Patient Satisfaction on Overactive Bladder Treatment
- 107 Downloads
Purpose of Review
The purpose of this review is to review recent literature with regard to patient satisfaction with overactive bladder treatments.
The latest research looks into beta-3 agonist, Mirabegron, to treat OAB and sacral and pudendal neuromodulation for severe OAB.
Conservative management effectively alleviated OAB symptoms without the adverse effects of antimuscarinic medications. PFME appears to be the most successful treatment. Medical management continues to show efficacy but with very bothersome side effects in a substantial proportion of patients and with significant cost, leading to medical noncompliance and discontinuation of therapy. BTX-A injections and neuromodulation also are quite efficacious as a third-line treatment option for refractory OAB patients or patients who are no longer candidates for second-line therapy.
KeywordsOveractive bladder Patient satisfaction Anticholinergics Neuromodulation
Compliance with Ethical Standards
Conflict of Interest
Kimberly Tay and Dr. Aqsa Khan both declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Kobelt-Nguyen G, Johanesson M, Mattiasson A, et al. Correlations between symptoms of urge incontinence and scores of a generic quality of life instrument (SF-36) and health status measurement (Euro-QoL) and between changes in symptoms and QoL scores [abstract]. Presented at the 27th Annual Meeting of The International Continence Society; September 23–26, 1997; Yokohama, Japan.Google Scholar
- 7.Abrams P, Wein AJ. The Overactive Bladder: A Widespread but Treatable Condition. Stockholm, Sweden: Erik Sparre Medical AB; 1998.Google Scholar
- 14.•• Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association, Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80. AUA/SUFU guidelines for overactive bladder management and proides an algorithm on how to manage patients and taking into account the quality of service.PubMedCrossRefGoogle Scholar
- 16.Aaron LE, Morris TJ, Jahshan P, Reiz JL. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Curr Med Res Opin. 2012;28(8):1369–79.PubMedCrossRefGoogle Scholar
- 20.Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Darekar A, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013;61(2):185–93.PubMedCrossRefGoogle Scholar
- 21.Sand PK, Heesakkers J, Kraus SR, Carlsson M, Guan Z, Berriman S. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging. 2012;29(2):119–31.PubMedCrossRefGoogle Scholar
- 22.DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn. 2012;31(8):1258–65.PubMedCrossRefGoogle Scholar
- 28.Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20.PubMedCrossRefGoogle Scholar
- 29.Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–32.PubMedPubMedCentralCrossRefGoogle Scholar
- 30.Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.PubMedCrossRefGoogle Scholar
- 31.Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–88.PubMedCrossRefGoogle Scholar
- 32.Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–57.PubMedCrossRefGoogle Scholar
- 38.Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J Urol. 2014;32(1):179–84.PubMedCrossRefGoogle Scholar
- 40.Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.PubMedCrossRefGoogle Scholar
- 42.Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation. Urology 2016 Apr 27.Google Scholar
- 44.Noblett K, Benson K, Kreder K. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Neurourol Urodyn 2016 Aug 4.Google Scholar
- 45.Hoag N, Plagakis S, Pillay S, Edwards AW, Gani J. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment. Neurourol Urodyn 2016 Sep 9.Google Scholar
- 46.Singh R, El Nashar SA, Trabuco EC, Klingele CJ, Gebhart JB, Occhino JA. Comparison of Short Term Outcomes of Sacral Nerve Stimulation and Intradetrusor Injection of OnabotulinumtoxinA (Botox) in Women With Refractory Overactive Bladder. Female Pelvic Med Reconstr Surg. 2015;21(6):369–73.PubMedCrossRefGoogle Scholar